Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors
February 06, 2023 at 08:31 am EST
Share
Halozyme Therapeutics, Inc. announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a
financial executive with significant leadership roles in the biopharmaceutical industry. Prior to Intercept, Ms. Duncan held senior leadership roles at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and Chief Executive Officer. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance -Global Healthcare at Lehman Brothers Inc. Ms. Duncan holds a Master of Business Administration from the Wharton School, University of Pennsylvania and a Bachelor of Business Administration in Accounting from Louisiana State University.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
HALOZYME THERAPEUTICS, INC. 
